A isoprenylcysteine (IPC) analog manufactured by biopharmaceutical company Signum Dermalogix Inc. (Dermalogix) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of rosacea.
The company filed an Investigational New Drug Application with the FDA to evaluate SIG990 for rosacea. SIG990 is a topical treatment that addresses both erythema and inflammatory lesions and thus would be a therapeutic option for those that suffer with rosacea.
SIG990 is an IPC analog that modulates toll-like receptor and G-protein signaling. It has demonstrated promising results in several in vitro cell based assays and efficacy in in vivo topical inflammatory animal models. Instrumental in the pre-clinical development of SIG990 was funding from the National Institute of Allergy and Infectious Diseases (NIAID) via an SBIR grant.
As a new chemical entity, SIG990 recently had composition of matter IP awarded (US Patent Application No. 12/566,839).
"We continue to make significant progress and are well-positioned to advance the development of our IPC compounds in dermatology. I look forward to moving SIG990 into the clinic to assess its efficacy in human subjects," noted Maxwell Stock, CEO of Dermalogix.